What Is Tirzepatide?
A Dual Agonist That Outperforms Single GLP-1 Therapies
Tirzepatide is a novel once-weekly injectable that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism produces greater appetite suppression, more significant improvements in insulin sensitivity, and higher average weight loss compared to GLP-1-only drugs. In the SURMOUNT-1 clinical trial, participants on the highest tirzepatide dose lost an average of 22.5% of their body weight — the largest ever seen in a randomized controlled weight-loss trial. Indianapolis patients seeking maximum results often choose tirzepatide as their first-line therapy.
Activates both GLP-1 and GIP receptors for dual metabolic benefit
Average 20–22% body weight loss at maximum dose in clinical trials
Once-weekly subcutaneous injection
Improves blood sugar, triglycerides, and blood pressure
Compounded tirzepatide at transparent direct-pay pricing
Dose titration from 2.5 mg up through 15 mg over time
